PharmAthene, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 10   

Articles published

PIP 1.28 -0.03 (-2.29%)
price chart
PharmAthene Vs. SIGA: Rebutting G. Hudson's 'Potential Award' Article
G. Hudson makes four claims, leading him to conclude that PharmAthene will receive reliance damages. Hudson is right about one claim, but because he is wrong about the other three, his conclusion doesn't follow logically.
PharmAthene Vs. SIGA: Responding To J. Eiseman's Rebuttal Article
City of New York, the New York Court of Appeals established that New York law limits a plaintiff to reliance damages for breach of an agreement to negotiate, without distinguishing between Type I and Type II agreements.86 In Fairbrook Leasing, Inc. v.
Related articles »  
Hot News : VIVUS (NASDAQ:VVUS), Google (NASDAQ:GOOG), PharmAthene ...
On JULY 9, Zacks reaffirmed their outperform rating on shares of VIVUS Inc (NASDAQ:VVUS) in a report issued on Tuesday. They currently have a $6.00 target price on the stock.
Theraclone Sciences makes deal with Gilead
... to neutralize viruses, such as HIV, that are known to mutate and evade current therapies,� said Clifford Stocks, CEO of Theraclone, in a statement.
Related articles »  
Explanation Of Potential Damage Award In PharmAthene Versus Siga Lawsuit
TM Techs., Inc., 1995 WL 130743, at *11 (Del. Ch. Mar. 16, 1995). The defendant fraudulently hid an improvement from the plaintiff, and applied for its own patents based on the improvement.
Related articles »  
Biotech Unsual Volume: Exelixis (NASDAQ:EXEL), Targacept (NASDAQ:TRGT ...
On 9 June PharmAthene, Inc. (NYSEMKT:PIP) announced that the U.S. Patent and Trademark Office issued U.S. patent number 8,729,245 to PharmAthene, with claims that cover methods for the production of its recombinant butyrlcholinesterase ...
Related articles »  
Pharmathene Inc receives FDA notification on sparvax
Pharmathene Inc Receives FDA Notification On SparVax